Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function.
Vaxxas develops needle-free HD-MAP patches that use microprojections to deliver medicine directly to immune cells beneath the skin.
Mirugen is a preclinical biotechnology company identifying the optimal set of cellular instructions to ask one cell type to become another.
AdvanCell is a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment.
Okogen is a developer of ophthalmic anti-infective drugs.
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
Myricx Bio is a biotechnology company that develops novel NMT inhibitor payloads for ADCs to treat cancer.
Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.
AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
Cincera Therapeutics is a privately held biotechnology company.
Perx is a digital care management program that motivates high-risk members to stick to their care plans.
OccuRx is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies.
George Medicines is a drug manufacturing company that improves the management of non-communicable diseases.
Denteric is developing a vaccine based on research conducted at the University of Melbourne.
TamoRx is a Biotech company that is focused on research and development of biological mechanism within cells for cancer treatment.
Amaroq Therapeutics is a biotech firm developing cancer therapies targeting long non-coding RNAs.
Axelia Oncology is a biopharmaceutical company provides transformation of treatment of insensitive cancers.
Certa Therapeutics is a clinical stage biotechnology company developing innovative therapies for the treatment of fibrotic diseases.
Auspherix is an Australian early stage anti-infectives company developing novel antibiotics to treat resistant bacterial diseases.
Brandon Capital has invested in 45 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Brandon Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 14 different industry categories.
Among tracked funding rounds, CatalYm received $150.0M in a Series D round. Brandon Capital's total known invested capital is $1.1B.
Brandon Capital's average investment size is $28.3M across its portfolio of 45 companies.
Recent Brandon Capital portfolio additions include NRG Therapeutics, Vaxxas, Mirugen, AdvanCell, Okogen. These companies were founded in 2020 or later.